Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NR1D1 | P20393 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11537633 | 0.77 | KMT2A (0.49) | NR1D1MAPTKDM4EHTTGAA | |
| SCHEMBL7474007 | 0.76 | HPGD (0.58) | HPGDMAPTHTTGAAL3MBTL1 | |
| SCHEMBL4903733 | 0.76 | HPGD (0.58) | HPGDMAPTKDM4EHTTGAA | |
| SCHEMBL13838136 | 0.76 | HPGD (0.58) | HPGDMAPTHTTKMT2AALDH1A1 | |
| SCHEMBL17203308 | 0.76 | TRPV1 (0.60) | HPGDMAPTHTTKMT2AALDH1A1 | |
| SCHEMBL8654197 | 0.75 | KMT2A (0.48) | NR1D1MAPTKDM4EHTTGAA | |
| SCHEMBL13838139 | 0.75 | HPGD (0.89) | HPGDMAPTKDM4EHTTGAA | |
| SCHEMBL6152881 | 0.74 | KMT2A (0.47) | NR1D1MAPTKDM4EHTTGAA | |
| SCHEMBL1351134 | 0.74 | LMNA (0.55) | HPGDMAPTL3MBTL1POLBKMT2A | |
| SCHEMBL2224980 | 0.74 | HPGD (0.56) | HPGDMAPTHTTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | BOSCHELLI DIANE H | 2008-03-20 | — | — | US | disclosed |
| US-7276519-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-6987116-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2006-01-17 | — | — | US | disclosed |
| CN-1714092-A | Thieno [3, 2-b ] pyridine-6-carbonitriles and thieno [2, 3-b ] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH CORP (US) | 2005-12-28 | — | — | CN | disclosed |
| EP-1565474-A2 | THIENO[3,2-B]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048386-A9 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2004-12-02 | — | — | US | disclosed |
| US-20040138251-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2004-07-15 | — | — | US | disclosed |
| WO-2004048386-A2 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, TNNI3K, PKN1 | HPGD 2649/4885NR1D1 1721/4885MAPT 3856/4885 |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, PTK2B, PKN1 | HPGD 2218/4885NR1D1 1207/4885MAPT 3782/4885 |
| US-20040138251-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | PTK2B, PKD1, PKN1 | HPGD 1872/4885NR1D1 1201/4885MAPT 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.